Earlier this year, we posted two articles about the work of Michael Whitt, Associate Dean of the Office of Medical Education in the College of Medicine at the University of Tennessee (UT) Health Science Center and Professor of Microbiology, Immunology and Biochemistry.
One of those posts from early April described recognition that Whitt received from the “Better World Project” of AUTM, the 3,100-member organization of technology managers from around the globe. The other article, posted in February, discussed the way that Moderna was utilizing a reverse genetics system that Whitt developed and patented in the 1990s that allows researchers to study highly pathogenic viruses under standard biosafety level 2 containment.
In the latest issue of its newsletter, the UT Research Foundation spotlights a new hybrid agreement that the organization developed and executed with Moderna to leverage technology, expertise and materials from UTHSC. This collaboration allows Moderna to better fight SARS-CoV-2 and evaluate its vaccine against new variants.